A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
Sjoerd J FinnemaSamantha RossanoMika NaganawaShannan HenryHong GaoRichard PracittoRalph P MaguireJoël MercierSophie KervynJean-Marie NicolasHenrik KlitgaardSteven DeBruynChristian OtoulPaul MartinPierandrea MugliaDavid MatuskeyNabeel B NabulsiYiyun HuangRafal M KaminskiJonas HannestadArmel StockisRichard E CarsonPublished in: Epilepsia (2019)
BRV achieves high SO more rapidly than LEV when intravenously administered at therapeutic doses. Thus, BRV may have utility in treating acute seizures; further clinical studies are needed for confirmation.